• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

EClinicalMedicine . Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019

tetano

Editor, Senior Moderator
EClinicalMedicine


. 2021 Apr 15;100829.
doi: 10.1016/j.eclinm.2021.100829. Online ahead of print.
Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019


Sylvia Ranjeva[SUP] 1 [/SUP], Riccardo Pinciroli[SUP] 1 [/SUP], Evan Hodell[SUP] 1 [/SUP], Ariel Mueller[SUP] 1 [/SUP], C Corey Hardin[SUP] 2 [/SUP], B Taylor Thompson[SUP] 2 [/SUP], Lorenzo Berra[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Acute respiratory distress syndrome (ARDS) secondary to coronavirus disease-2019 (COVID-19) is characterized by substantial heterogeneity in clinical, biochemical, and physiological characteristics. However, the pathophysiology of severe COVID-19 infection is poorly understood. Previous studies established clinical and biological phenotypes among classical ARDS cohorts, with important therapeutic implications. The phenotypic profile of COVID-19 associated ARDS remains unknown.
Methods: We used latent class modeling via a multivariate mixture model to identify phenotypes from clinical and biochemical data collected from 263 patients admitted to Massachusetts General Hospital intensive care unit with COVID-19-associated ARDS between March 13 and August 2, 2020.
Findings: We identified two distinct phenotypes of COVID-19-associated ARDS, with substantial differences in biochemical profiles despite minimal differences in respiratory dynamics. The minority phenotype (class 2, n = 70, 26?6%) demonstrated increased markers of coagulopathy, with mild relative hyper-inflammation and dramatically increased markers of end-organ dysfunction (e.g., creatinine, troponin). The odds of 28-day mortality among the class 2 phenotype was more than double that of the class 1 phenotype (40?0% vs.? 23?3%, OR = 2?2, 95% CI [1?2, 3?9]).
Interpretation: We identified distinct phenotypic profiles in COVID-19 associated ARDS, with little variation according to respiratory physiology but with important variation according to systemic and extra-pulmonary markers. Phenotypic identity was highly associated with short-term mortality. The class 2 phenotype exhibited prominent signatures of coagulopathy, suggesting that vascular dysfunction may play an important role in the clinical progression of severe COVID-19-related disease.

Keywords: ARDS; COVID-19; Phenotypes; Statistical inference.
 
Back
Top Bottom